Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Global Forecast 2023-2030
The Cancer Diagnostics Market is projected to reach USD 65.06 billion by 2030 from USD 27.03 billion in 2022, at a CAGR of 11.60% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Cancer Diagnostics Market.
- Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays. The Imaging Tests commanded largest market share of 37.76% in 2022, followed by Biopsy.
- Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer. The Lung Cancer commanded largest market share of 19.99% in 2022, followed by Breast Cancer.
- Based on Components, market is studied across Consumables, Instruments, and Software. The Instruments commanded largest market share of 74.75% in 2022, followed by Consumables.
- Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers. The Hospitals commanded largest market share of 52.45% in 2022, followed by Diagnostic Laboratories.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.45% in 2022, followed by Americas.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Cancer Diagnostics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Cancer Diagnostics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMérieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Cancer Diagnostics Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Cancer Diagnostics Market?
- What is the competitive strategic window for identifying opportunities in the Cancer Diagnostics Market?
- What are the latest technology trends and regulatory frameworks in the Cancer Diagnostics Market?
- What is the market share of the leading vendors in the Cancer Diagnostics Market?
- Which modes and strategic moves are suitable for entering the Cancer Diagnostics Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Cancer Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing burden of cancer among younger and geriatric population
- 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
- 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
- 5.1.2. Restraints
- 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
- 5.1.3. Opportunities
- 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
- 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
- 5.1.4. Challenges
- 5.1.4.1. Inadequate and false results of cancer diagnostics
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Cancer Diagnostics Market, by Diagnostic Type
- 6.1. Introduction
- 6.2. Biopsy
- 6.3. Blood Chemistry Tests
- 6.4.1. Complete Blood Count (CBC)
- 6.4.2. Cytogenetic Analysis
- 6.4.3. Immunophenotyping
- 6.4.4. Liquid Biopsy
- 6.4.5. Sputum Cytology
- 6.4.6. Tumor Marker Tests
- 6.4.7. Urine Cytology
- 6.4. Imaging Tests
- 6.5.1. Bone Scan
- 6.5.2. CT-Scan
- 6.5.3. Magnetic Resonance Imaging (MRI)
- 6.5.4. Nuclear Scan
- 6.5.5. Positron Emission Tomography (PET) Scan
- 6.5.6. Ultrasound
- 6.5.7. X-Rays
- 7. Cancer Diagnostics Market, by Indication
- 7.1. Introduction
- 7.2. Bladder Cancer
- 7.3. Blood Cancer
- 7.4. Breast Cancer
- 7.5. Colorectal Cancer
- 7.6. Kidney Cancer
- 7.7. Liver Cancer
- 7.8. Lung Cancer
- 7.9. Pancreatic Cancer
- 7.10. Prostate Cancer
- 7.11. Skin Cancer
- 8. Cancer Diagnostics Market, by Components
- 8.1. Introduction
- 8.2. Consumables
- 8.3. Instruments
- 8.4. Software
- 9. Cancer Diagnostics Market, by End-Use
- 9.1. Introduction
- 9.2. Diagnostic Laboratories
- 9.3. Hospitals
- 9.4. Research Centers
- 10. Americas Cancer Diagnostics Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Cancer Diagnostics Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Cancer Diagnostics Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Biocare Medical Acquires Empire Genomics
- 13.3.1.2. Thermo Fisher ties up $2.6B deal for The Binding Site
- 13.3.1.3. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
- 13.3.1.4. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
- 13.3.1.5. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
- 13.3.2.2. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
- 13.3.2.3. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
- 13.3.2.4. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. Ibex Medical launches Galen 3.0 cancer diagnostics platform
- 13.3.3.2. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
- 13.3.4. Investment & Funding
- 13.3.4.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
- 13.3.4.2. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
- 13.3.4.3. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
- 13.3.5.2. Karkinos Healthcare launches ‘Advanced Centre For Cancer Diagnostics and Research'
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Adaptive Biotechnologies Corporation
- 14.1.3. Agilent Technologies, Inc.
- 14.1.4. Becton, Dickinson & Company
- 14.1.5. Bio-Techne Corporation
- 14.1.6. bioMérieux SA
- 14.1.7. Castle Biosciences Inc.
- 14.1.8. Danaher Corporation
- 14.1.9. Exact Sciences Corporation
- 14.1.10. F. Hoffmann-La Roche Ltd.
- 14.1.11. GE Healthcare
- 14.1.12. Hologic Inc.
- 14.1.13. Illumina, Inc.
- 14.1.14. Johnson & Johnson Services, Inc.
- 14.1.15. Konica Minolta, Inc.
- 14.1.16. Koninklijke Philips N.V.
- 14.1.17. Myriad Genetics
- 14.1.18. Natera, Inc.
- 14.1.19. Perkin Elmer, Inc.
- 14.1.20. Personal Genome Diagnostics Inc.
- 14.1.21. Qiagen N.V.
- 14.1.22. Quest Diagnostics
- 14.1.23. Siemens Healthineers AG
- 14.1.24. Sysmex Corporation
- 14.1.25. Thermo Fisher Scientific, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook